Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis
Announced top-line data for AMT-101 MARKET Phase 2 combination trial in patients with moderate-to-severe ulcerative colitis (UC)
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis
Announced top-line data for AMT-101 MARKET Phase 2 combination trial in patients with moderate-to-severe ulcerative colitis (UC)
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| AMTI | 0.2630 | -0.0439 | -14.30% |
| Applied Molecular Transport Inc | |||